Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, has announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma. Continue reading ...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment